BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

  June 1, 2026

   · 

  9 min read
• Press Releases

  Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

  June 1, 2026

   · 

  15 min read
• Press Releases

  Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC

  June 1, 2026

   · 

  3 min read
• Press Releases

  United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026

  June 1, 2026

   · 

  3 min read
• Press Releases

  Ainnocence Proposes a Seven-Rule Governance Framework and Value Scorecard for AI-Driven Drug Discovery

  CEO and Founder Dr. Lurong Pan calls on the AI pharmaceutical industry to set boundaries for the algorithm, pairing executable safety rules with an honest, two-dimensional method for measuring what a model actually contributes

  June 1, 2026

   · 

  1 min read
• Press Releases

  Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026

  June 1, 2026

   · 

  13 min read
• Press Releases

  Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

  June 1, 2026

   · 

  9 min read
• Press Releases

  Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

  June 1, 2026

   · 

  9 min read
• Press Releases

  Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

  June 1, 2026

   · 

  10 min read
• Press Releases

  TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026

  June 1, 2026

   · 

  5 min read